trending Market Intelligence /marketintelligence/en/news-insights/trending/uxvhtmrrsmm2pkcuzpyr4q2 content esgSubNav
In This List

Akebia Therapeutics plans $85M common stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Akebia Therapeutics plans $85M common stock offering

Akebia Therapeutics Inc. plans to sell $85 million of its common shares in an underwritten public offering.

The company also plans to give the underwriter an option to buy up to an additional $12.8 million of shares.

Akebia plans to use the net proceeds for the continued clinical development and optimization of the vadadustat program, including pre-commercial planning activities, and the remainder for working capital, business development and other general corporate purposes.

Morgan Stanley is acting as sole book-running manager for the offering.